A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants - Concepedia

Concepedia

Publication | Open Access

A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

DOI Full Paper Access

63

Citations

31

References

2020

Year

Heather Platt, David Greenberg, Bruce Tapiéro, Robert Clifford, Nicola P. Klein, David Hurley, Tulin Shekar, Jianing Li, Kim Hurtado, Shu‐Chih Su,

The Pediatric Infectious Disease Journal

Abstract

Immunogenicity of both V114 lots was noninferior to PCV13 for all 13 shared serotypes between the 2 vaccines and displayed comparable safety and tolerability profiles to PCV13.

References

	Year	Citations

Page 1